198 related articles for article (PubMed ID: 35890277)
1. Comparative Characterization of Different Molecular Formats of Bispecific Antibodies Targeting EGFR and PD-L1.
Mohan N; Agrawal A; Shen Y; Winarski KL; Endo Y; Dokmanovic M; Schmiel D; Zheng J; Rotstein DS; Pelosof LC; Wu WJ
Pharmaceutics; 2022 Jun; 14(7):. PubMed ID: 35890277
[TBL] [Abstract][Full Text] [Related]
2. Anti-PD-L1-Based Bispecific Antibodies Targeting Co-Inhibitory and Co-Stimulatory Molecules for Cancer Immunotherapy.
Geng Q; Jiao P
Molecules; 2024 Jan; 29(2):. PubMed ID: 38257366
[TBL] [Abstract][Full Text] [Related]
3. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells.
Pandey MS; Wang C; Umlauf S; Lin S
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768776
[TBL] [Abstract][Full Text] [Related]
5. Ion Mobility-Mass Spectrometry and Collision-Induced Unfolding of Designed Bispecific Antibody Therapeutics.
Villafuerte-Vega RC; Li HW; Slaney TR; Chennamsetty N; Chen G; Tao L; Ruotolo BT
Anal Chem; 2023 May; 95(17):6962-6970. PubMed ID: 37067470
[TBL] [Abstract][Full Text] [Related]
6. Nanocell targeting using engineered bispecific antibodies.
Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
[TBL] [Abstract][Full Text] [Related]
7. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
8. Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies.
Loh HP; Mahfut FB; Chen SW; Huang Y; Huo J; Zhang W; Lam KP; Xu S; Yang Y
MAbs; 2023; 15(1):2231129. PubMed ID: 37403264
[TBL] [Abstract][Full Text] [Related]
9. Excellent removal of knob-into-hole bispecific antibody byproducts and impurities in a single-capture chromatography.
Chen SW; Hoi KM; Mahfut FB; Yang Y; Zhang W
Bioresour Bioprocess; 2022 Jul; 9(1):72. PubMed ID: 38647639
[TBL] [Abstract][Full Text] [Related]
10. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I
Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485
[TBL] [Abstract][Full Text] [Related]
11. A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective against Triple Negative Breast Cancer via Multiple Mechanisms of Action.
Mohan N; Luo X; Shen Y; Olson Z; Agrawal A; Endo Y; Rotstein DS; Pelosof LC; Wu WJ
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33804477
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody.
Watanabe Y; Asano R; Arai K; Shimomura I; Ogata H; Kawaguchi H; Hayashi H; Ohtsuka H; Yoshida H; Katayose Y; Egawa S; Nakanishi T; Umetsu M; Yasui H; Ishida T; Imai K; Kudo T; Unno M; Kumagai I
Oncol Rep; 2011 Oct; 26(4):949-55. PubMed ID: 21743971
[TBL] [Abstract][Full Text] [Related]
13. Generation and Characterization of a Bispecific Antibody Targeting Both PD-1 and c-MET.
Wu Y; Yu M; Sun Z; Hou W; Wang Y; Yuan Q; Mo W
Protein Pept Lett; 2018 Feb; 24(12):1105-1112. PubMed ID: 29046141
[TBL] [Abstract][Full Text] [Related]
14. Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody.
Zheng S; Moores S; Jarantow S; Pardinas J; Chiu M; Zhou H; Wang W
MAbs; 2016; 8(3):551-61. PubMed ID: 26761634
[TBL] [Abstract][Full Text] [Related]
15. RUBY® - a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties.
Nyesiga B; Levin M; Säll A; Rosén A; Jansson K; Fritzell S; Hägerbrand K; Weilguny D; von Schantz L
MAbs; 2024; 16(1):2330113. PubMed ID: 38527972
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.
Michaelson JS; Demarest SJ; Miller B; Amatucci A; Snyder WB; Wu X; Huang F; Phan S; Gao S; Doern A; Farrington GK; Lugovskoy A; Joseph I; Bailly V; Wang X; Garber E; Browning J; Glaser SM
MAbs; 2009; 1(2):128-41. PubMed ID: 20061822
[TBL] [Abstract][Full Text] [Related]
17. Rapid Generation of Murine Bispecific Antibodies Using FAST-Ig
Koga H; Kuroi H; Hirano R; Hirayama H; Nabuchi Y; Kuramochi T
Antibodies (Basel); 2024 Jan; 13(1):. PubMed ID: 38247567
[TBL] [Abstract][Full Text] [Related]
18. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
Park JA; Cheung NV
J Hematol Oncol; 2020 Dec; 13(1):172. PubMed ID: 33303017
[TBL] [Abstract][Full Text] [Related]
19. Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies.
You G; Won J; Lee Y; Moon D; Park Y; Lee SH; Lee SW
Vaccines (Basel); 2021 Jul; 9(7):. PubMed ID: 34358141
[TBL] [Abstract][Full Text] [Related]
20. Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formats.
Madsen AV; Kristensen P; Buell AK; Goletz S
MAbs; 2023; 15(1):2189432. PubMed ID: 36939220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
